Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pharmacologic Interaction Between Ifosfamide and Aprepitant in Treated Patients With Soft Tissue Sarcoma
Sponsor: Institut Claudius Regaud
Summary
This trial is a multicentric study aiming to assess the evolution of the serum ifosfamide concentrations and its serum metabolites in patients treated for an Soft Tissue Sarcoma and co-exposed to Aprepitant. The study will be conducted on a population of patients treated with Doxorubicin and Ifosfamide. The Aprepitant can be prescribed to patients from cycle 2, according to the current recommendations. Doxorubicin, Ifosfamide and Aprepitant will be administered in the context of routine care. The follow-up during the treatment period and the clinical, biological and radiological assessments will be performed according to the standard of each centre. Patients will be followed during the two first cycles of treatment. For the pharmacokinetic study, blood samples will be collected at different time points during the 2 treatment cycles.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
59
Start Date
2018-05-18
Completion Date
2020-11-23
Last Updated
2026-04-14
Healthy Volunteers
No
Conditions
Interventions
Patients starting a treatment with Doxorubicin and Ifosfamide
9 blood samples will be collected at each Cycle: * Cycle 1 (Day 1-Day 2-Day 3) * Cycle 2 (Day 1-Day 2-Day 3)
Locations (3)
Institut Bergonie
Bordeaux, France
Institut Regional Du Cancer de Montpellier (Icm)
Montpellier, France
Institut Universitaire Du Cancer de Toulouse - Oncopole
Toulouse, France